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Abstract
Background: Dose intensity and dose density of first line Platinum and Etoposide (PE) do not influence Overall
Survival (OS) of Small Cell Lung Cancer (SCLC) patients. The effect of treatment length, however, remains unclear.
Current guidelines recommend treating beyond 4 cycles -up to 6-, in patients that respond to and tolerate systemic
treatment. This has led to variable practice both in clinical practice and clinical research. Here we aimed at quantifying
the possible clinical benefit of the extended regimen in our real-life patients treated with PE doublet.
Methods: Of all patients with SCLC treated in our network with non-concurrent first line PE chemotherapy between
2008 and 2015, we identified and described patients that received 4 cycles (4c) or more (> 4c), and analysed patients
with stage IV disease.
Results: Two hundred forty-one patients with stage IV had 4c and 69 had > 4c. The latter were more likely to have
sequential thoracic radiotherapy, which suggested a lower metastatic burden. Nevertheless, there were no statistically
significant differences when comparing clinical outcomes. The median Duration of Response (DoR; time from
last chemotherapy cycle to progression) was 5 months in both groups (HR 1.22; 95% CI 0.93–1.61). Median Progression
Free Survival (PFS; time from diagnosis to radiological progression) was 8 months (4c) versus 9 months (> 4c) (HR 0.86;
95% CI 0.66–1.13) and median OS was 11 versus 12months (HR 0.86, 95% CI 0.66–1.14).
Conclusion: Our results highlight a lack of clinical benefit by extending first line PE treatment in stage IV disease, and
support limiting treatment to 4 cycles until superiority of a longer regimen is identified in a randomised study.
Keywords: Lung neoplasm, Small cell lung carcinoma, Drug therapy, Observational study, Antineoplastic combined
chemotherapy protocols
Background
Small Cell Lung Cancer (SCLC) is the most common neu-
roendocrine tumour of the lung [1] and accounts for 10% of
all lung cancers [2]. Its incidence is associated with smoking,
almost two thirds of patients present with advanced disease
[3], and although response rates to chemotherapy are high,
the benefit is short-lived. With platinum and etoposide (PE)
chemotherapy combination in extensive disease the median
progression-free survival (PFS) is only 5.5months and the
median overall survival (OS) under 10months [4]. These
figures underline the need to optimise oncological treat-
ment in SCLC, so that survival benefit is maximised whilst
unnecessary treatment and toxicity are avoided.
When SCLC is not amenable to concurrent chemora-
diotherapy, international guidelines advice 4 to 6 cycles
of first line systemic Platinum (Cisplatin or Carboplatin)
and Etoposide combination (PE) [5, 6]. Prophylactic
Cranial Irradiation (PCI) [7], and sequential thoracic
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radiotherapy may be considered in patients with ei-
ther limited [8, 9] or extensive disease [10].
So far, in SCLC more chemotherapy does not translate
in more clinical benefit. Strategies increasing chemother-
apy dose intensity, dose density, peak dose or total dose
regimens have been studied extensively and failed to
provide a survival advantage [11]. Randomised clinical
trials differ in identifying a survival benefit with main-
tenance Topotecan or Etoposide after 4 cycles of plat-
inum combination [12, 13]. Two meta-analysis [14, 15]
concur with a potential impact in PFS in extensive
disease but differ in its survival benefit. Although main-
tenance treatment may be common practice in some
countries [14] international guidelines discourage its
use [5, 6].
The length of first line PE treatment, however, remains
controversial. In the early 80’s, 6 cycles of Vincristine,
Doxorubicin and Cyclophosphamide (CAV) were the
standard of care. A decade later Roth et al. [16] run a
randomized phase III study with over 437 eligible
patients. They compared 4 cycles of Cisplatin and Eto-
poside with 6 cycles of CAV and 6 cycles of a hybrid
regimen of CAV and Cisplatinum-Etoposide. No PFS or
survival differences were identified, but a higher rate of
infection was found in CAV containing regimens. The
only study that compared 4 versus 6 cycles of Cisplatin
and Etoposide chemotherapy was published a few years
later by Veslemes et al. [17]. Sixty-nine of the 70 rando-
mised patients were analysded, and only 46 had exten-
sive disease. The primary objective of the study was
undisclosed, and there was no pre-planned subgroup
analysis. Anyhow, no significant survival differences were
identified other than a trend to survival gain in patients
with extensive disease at the expense of higher toxicity.
Chasing this possible benefit with a longer regimen ap-
peared less intricate when outpatient Carboplatin con-
taining doublet administration showed similar clinical
benefit than the then inpatient Cisplatin based treatment
[18, 19].
International guidelines [5, 6] continue to encourage
the use of a range of chemotherapy cycle numbers.
Nonetheless, this promotes variability in real-life practice
and clinical research. For example, some randomised
studies may use 4 cycles as standard of care control [12,
13], while others may design their study to optimise the
delivery of 6 cycles [20].
Perhaps due to the limited evidence available, the opti-
mal length of first line platinum combination treatment
in recent reviews is either omitted [21–23] or mainten-
ance treatment is discussed instead [24]. The drastically
inferior benefit of second line options [5, 24] and the
low impact of novel biological approaches so far [23] are
factors that may influence treatment attitudes towards
the length of this first line setting. This is unlikely to
change in spite of the recent introduction of first-line
immune therapy combination with 4 cycles of chemo-
therapy [25]: as long as the backbone of cytotoxic
chemotherapy remains, the possibility of extending
cytotoxic chemotherapy to 6 cycles will remain
unchanged for as long as the perception of benefit
remains unchallenged. Furthermore, extending PE
chemotherapy in patients that are not amenable to
first-line immune therapy combination may be the
only option to attempt to optimise their survival
benefit. In this context a prospective study is unlikely
to materialize, and retrospective analysis of real-life
patients is the only method available to identify the
optimal treatment length.
The Merseyside and Cheshire Cancer Network serves
a population of 2.3 million with non-surgical oncology
provision and receives over 1000 new lung cancer refer-
rals per year. Of those that receive treatment in our
centre, audit data is recorded prospectively. Practice
amongst oncologists is diverse and some advocate for
treatment continuation beyond 4 cycles in selected
patients. Here we aim at characterising that subpopula-
tion and quantifying the possible survival gain over a
four-cycle regimen.
Methods
This was a retrospective observational study of the Mer-
seyside and Cheshire Cancer Network. Audit approval
was obtained ahead of data collection according to local
policy. Patients referred with pathologically confirmed
small cell lung cancer and treated with Platinum and
Etoposide combination regimens over an 8-year period
(2008–2015) were identified. The first date was chosen
to optimise prospective data record consistency, and the
latter to allow mature one-year survival data. Two thou-
sand fifteen also preceded the use of standard consolida-
tion radiotherapy in extensive disease [10]. Patients treated
with concurrent chemo-radiotherapy, non-platinum-based
combination or single agent platinum, were excluded.
Epidemiological, pathological, treatment and survival
data were extracted from the prospective database and
confirmed retrospectively. Radiological response and
progression was collected retrospectively. Lung radiother-
apy was defined as radiotherapy administered to the pri-
mary lung tumour any time after systemic chemotherapy
regardless of intent. Analysis on treatment outcomes were
performed for stage IV SCLC (n = 69 for > 4c and n = 241
for 4c). Progression was defined as the date of radiological
progression. Duration of Response (DoR) was defined as
the time from the date of administration of the last cycle
of chemotherapy to the date of progression or death.
Progression Free Survival (PFS) was defined as the time
from diagnosis to progression or death. Overall Survival
Sallam et al. BMC Pulmonary Medicine          (2019) 19:195 Page 2 of 8
(OS) was defined as time from diagnosis to death or last
patient review.
Chi-square contingency analysis was performed to
identify epidemiological or treatment variables. PFS
and OS curves were constructed using the Kaplan-
Meier method, and compared for significance using the
log-rank test. A cox proportional hazards model was used
to generate univariate hazard ratios (HR) and 95% confi-
dence intervals. A two-sided p < 0.05 was considered as
statistically significant. All statistical analyses were carried
out using the statistics software IBM SPSS v.24.0 (SPSS
Inc.).




Of the 671 patients that received systemic PE combin-
ation treatment without concurrent radiotherapy, 93
were selected to have more a longer regimen, of which
24 (26%) had an initial stage of I-III -half of them (n =
12, 13%) with limited disease-, and 69 (74%) had stage
IV disease. When comparing patients that had 4 cycles
(4c) (n = 578) versus those that went on to have more
than 4 (> 4c) (n = 93), significant differences were identi-
fied in their co-morbidity, stage and disease extent (see
Table 1) as well as the proportion of second line chemo-
therapy received (see Table 2), but there were no differ-
ences in their best response rates to treatment. Patients
selected to have a longer treatment had less co-
morbidity, more advanced stage and were eventually less
likely to receive second line chemotherapy. These differ-
ences were not apparent when comparing patients that
presented with stage IV disease, of which 241 completed
4 cycles and 69 completed more than 4. Hence, we de-
cided to focus in these more homogeneous sub-
population of patients with stage IV disease for outcome
analysis (see Fig. 1).
In patients with stage IV both treatment groups had a
similar sex distribution and an average age of 65; around
Table 1 Demographic characteristics. Percentage relative to the total at the top row is presented in brackets. Chi-square
contingency analysis was performed where indicated. Statistically significant results are highlighted in italic and an asterisk
All patients Extensive Disease Stage IV
>4 cycles 4 cycles p value >4 cycles 4 cycles p value >4 cycles 4 cycles p value
Total N 93 578 81 402 69 241
Sex, n (%) 0.115 0.113 0.218
Male 48 (51.6) 246 (42.6) 43 (53.1) 174 (43.3) 37 (53.6) 107 (44.4)
Female 45 (48.4) 332 (57.4) 38 (46.9) 228 (56.7) 32 (46.4) 134 (55.6)
Age, Avg [Min-Max] 65 [39–81] 66 [37–88] 0.847 65 [39–80] 66 [37–88] 0.358 65 [39–80] 65 [41–87] 0.812
PS, n (%) 0.426 0.367 0.192
PS0 14 (15.1) 64 (11.1) 14 (17.3) 45 (11.2) 14 (20.3) 29 (12)
PS1 41 (44.1) 288 (49.8) 33 (40.7) 189 (47) 26 (37.7) 122 (50.6)
PS2 34 (36.6) 205 (35.5) 30 (37) 149 (37.1) 25 (36.2) 83 (34.4)
PS3 3 (3.2) 20 (3.5) 3 (3.7) 18 (4.5) 3 (4.3) 6 (2.5)
PS4 1 (1.1%) 1 (0.2%) 1 (1.2%) 1 (0.2%) 1 (1.4%) 1 (0.4%)
Comorbidities, n (%) 0.01* 0.017* 0.140
None 26 (28) 85 (14.7) 21 (25.9) 60 (14.9) 17 (24.6) 37 (15.4)
Mild 40 (43) 320 (55.4) 35 (43.2) 222 (55.2) 33 (47.8) 134 (55.6)
Moderate 24 (25.8) 162 (28) 23 (28.4) 111 (27.6) 17 (24.6) 66 (27.4)
Severe 3 (3.3) 11 (1.9) 2 (2.4) 9 (2.2) 2 (2.8) 4 (1.7)
Stage, n (%) < 0.001* < 0.001*
Stage I 1 (1.1) 11 (1.9) – – – – –
Stage II-III 23 (24.7) 326 (56.4) 12 (14.8) 161 (40) – –
Stage IV 69 (74.2) 241 (41.7) 69 (85.2) 241 (60) 69 (100) 241 (100)
Disease extent, n (%) < 0.001*
Limited 12 (12.9) 176 (30.4) – – – –
Extensive 81 (87.1) 402 (69.6) 81 (100) 402 (100) 69 (100) 241 (100)
SVCO at presentation 4 (4.3) 36 (6.2) 0.466 4 (4.9) 30 (7.5) 0.633 2 (2.9) 14 (5.8) 0.538
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40% had PS2 or more, and almost 30% had moderate or
severe co-morbidities. Most patients received
carboplatin-based chemotherapy: 97% in the 4c group
and 99% in the > 4c. In that latter group, 84% completed
6 cycles, reaching an average of 5.8 cycles. Again, re-
sponse rates were similar in both groups.
Whereas PCI rates were less than 40% in both groups,
the rates of radiotherapy to the lung were higher in the
patients treated with a longer regimen (25% in 4c versus
39% in > 4c). The intent of thoracic radiotherapy was in
all cases palliative. There were no differences in second
line treatment rates, and the proportion of platinum
Table 2 Treatment characteristics. Percentage relative to the total at the top row are presented in brackets. Chi-square contingency
analysis was performed where indicated. Statistically significant results are highlighted in italic and an asterisk
All patients Extensive Disease Stage IV
>4 cycles 4 cycles p value >4 cycles 4 cycles p value >4 cycles 4 cycles p value
Total N 93 578 81 402 69 241
1st Line Chemotherapy, n (%) 0.148 0.557 0.689
Cisplatin Etoposide 2 (2.2) 37 (6.4) 2 (2.5) 20 (5) 1 (1.4) 8 (3.3)
Carboplatin Etoposide 91 (97.8) 541 (93.6) 79 (97.5) 382 (95) 68 (98.6) 233 (96.7)
Cycle Number, n (%)
4 cycles – 578 (100) – 402 (100) – 241 (100)
5 cycles 13 (14) – 13 (16) – 11 (15.9) –
6 cycles 80 (86) – 68 (84) – 58 (84.1) –
Average Cycles 5.9 4 5.8 4 5.8 4
Response, n (%) 0.461 0.9807 0.538
Progression 3 (3.2) 13 (2.2) 3 (3.7) 12 (3) 2 (2.9) 8 (3.3)
Stable Disease 12 (12.9) 53 (9.2) 11 (13.6) 37 (9.2) 10 (14.5) 25 (10.4)
Partial Response 57 (61.3) 412 (71.3) 51 (63) 288 (71.6) 44 (63.8) 74 (72.2)
Complete Response 21 (22.6) 100 (17.3) 16 (18.9) 62 (15.4) 13 (18.8) 34 (14.1)
Radiotherapy to lung, n (%) 43 (46.2) 254 (43.9) 0.736 35 (43.2) 146 (36.3) 0.259 27 (39.1) 61 (25.3) 0.033*
PCI, n (%) 37 (39.8) 240 (41.5) 0.821 29 (35.8) 156 (38.8) 0.707 24 (34.8) 96 (39.8) 0.486
2nd line Chemotherapy, n (%) 17 (18.3) 167 (28.9) 0.034* 17 (21) 108 (26.9) 0.271 16 (23.2) 62 (25.7) 0.754
CarboEtop 7 (7.5) 88 (15.2) 0.804 7 (8.6) 47 (11.7) 0.796 6 (8.7) 29 (12) 1.000
Topotecan 4 (4.3) 15 (2.6) 4 (4.9) 5 (1.2) 4 (5.8) 4 (1.7)
CAV 6 (6.5) 62 (10.7) 6 (7.4) 42 (10.4) 6 (8.7) 28 (11.6)
3rd line Chemotherapy, n (%) 4 (4.3) 26 (4.5) 4 (4.9) 18 (4.5) 4 (5.8) 9 (3.7)
Fig. 1 Patient flow diagram
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re-challenge was 12% in the 4c group versus 9% in
the > 4c.
Treatment outcomes
The similar rate of platinum re-challenge was concord-
ant with the clinical outcomes measured: there were no
significant differences in duration of response (DoR),
progression free survival (PFS) or overall survival (OS)
in patients with stage IV disease.
DoR curves (time from the last cycle administration to
disease recurrence) for patients that completed first line
PE treatment are shown in Fig. 2, with a median DoR of
5 months in both groups. The HR for > 4c was 1.22 (95%
CI 0.93–1.61; p = 0.104), and the 6 month DoR was 48%
for the 4c group versus 33% for the > 4c.
PFS curves (see Fig. 3) show a median PFS of 8
(4c) versus 9 months (>4c), with an HR for >4c of
0.86 (95% CI 0.66–1.13; p = 0.225). Respectively, the
6-month PFS was 86% versus 96%, and the 1 year
PFS 20% versus 23%.
The median OS (see Fig. 4) was 11 months for the
patients in the shorter treatment and 12 months for the
longer schedule, with an HR for >4c of 0.86 (95% CI
0.66–1.14; p = 0.28). The one-year OS was 35 and 46%
respectively.
Discussion
To our knowledge, this is the largest study analysing the
effect of extending platinum doublet treatment beyond 4
cycles in patients with stage IV SCLC disease. Our
selected real-life patients with stage IV SCLC did not
improve disease control or survival by extending first
line platinum and etoposide combination treatment
beyond 4 cycles.
The retrospective nature of the study was an import-
ant limitation, restricting accurate quantification of the
timing of the treatment length decision - at presentation
or after 3–4 cycles -, and treatment toleration. The latter
was related to inter-consultant differences in patient
assessment as well as changes in standard toxicity
chemotherapy nurse documentation during the study
time. Noticeably, there was a low proportion of patients
that went on to complete more than 4 cycles of chemo-
therapy: only 93 (14%) of the 671 initial population and
69 (22%) of the 310 patients with stage IV. These
numbers suggested high patient selection, a bias that
would favour the longer treatment group. Nevertheless,
Fig. 2 Kaplan Meyer curve of time from last chemotherapy cycle to date of progression or death (DoR; Duration of Response)
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radiological response (the one measurable selection
criteria available) was similar in patients with stage IV
regardless of treatment length. This may have been due
to (a) inaccurate patient selection on radiological assess-
ment of response, (b) a fundamental reliance on treat-
ment toleration, or (c) a decision of treatment length
intent at presentation based on non-recorded criteria
such as clinical relevance of metastatic burden.
The latter possibility may have been evident when
exploring differences in subsequent treatment between
the groups. 39% (n = 27) of patients in the >4c group
went on to have palliative radiation to the lung,
whereas only 25% (n = 61) of the 4c group received
the same treatment. The clinical benefit in extensive
disease is limited [10], but may suggest a lower clin-
ical relevance of the metastatic burden in this particu-
lar subpopulation. In spite of this bias that would
favour the >4c population no differences in clinical
outcomes were observed.
Another potential bias inherent to retrospective stud-
ies is a suspected variability in the timing of patient
review and investigations during follow up, influencing
the diagnosis of recurrence. Still, there is no reason to
expect differences in follow up related to the length of
the first line treatment, hence we assumed equal distri-
bution of this bias in both treatment groups.
As expected, our PFS and OS values were better than
those previously reported [4]. Patients that received 3 or
less treatment cycles were not included and therefore
their outcome did not burden the clinical measures of
the populations studied here.
Caution is required when extrapolating our results to
patients with early stage disease, as there were only small
numbers in our long treatment cohort, and they were
excluded from clinical outcome calculations (see Fig. 1).
However, in view of the observed lack of benefit of a
longer treatment in extensive disease, and the lack of
prospective evidence of benefit in limited stage [17], it
would be reasonable to question the benefit of treating
beyond 4 cycles in patients with limited disease undergo-
ing sequential chemoradiotherapy.
Conclusion
Our real-life data in stage IV disease does not support
treatment beyond 4 cycles of PE combination. That is
consistent with the lack of benefit seen in randomised
prospective studies comparing 4 cycles with 6 cycles of
either a hybrid regimen [16] or cisplatin and etoposide
Fig. 3 Kaplan Meyer curve of time from diagnosis to date of disease progression or death (PFS; Progression Free Survival)
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[17]. Limiting treatment to 4 cycles may contribute
to avoid unnecessary hospital visits and toxicity,
optimise treatment cost-effectiveness and perhaps
increase the focus on recruitment into clinical trials
exploring novel strategies [26] with the potential of
improving survival outcomes.
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